ASH 2023 | Advancing MCL treatment: combination therapies and updates from SYMPATICO
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the latest advancements in novel treatment strategies for mantle cell lymphoma (MCL). Dr Cheah highlights the promising efficacy of the combination of ibrutinib plus venetoclax, as seen in the SYMPATICO trial (NCT03112174), as well as the emerging use of bispecific antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: MSD, TG therapeutics, AstraZeneca, Lilly, Janssen, Ascentage Pharma, Gilead, BeiGene, Novartis, BMS, Menarini, Roche, Genmab, Daizai
Honoraria: MSD, TG therapeutics, AstraZeneca, Lilly, Janssen, Ascentage Pharma, Gilead, BeiGene, Novartis, BMS, Menarini, Roche, Genmab, Daizai
Board of Directors/Advisory Committee: MSD, TG therapeutics, AstraZeneca, Lilly, Janssen, Ascentage Pharma, Gilead, BeiGene, Novartis, BMS, Roche
Research Funding: MSD, Lilly, BMS, AbbVie, Roche
Other: Roche
